EntryPoint Capital’s CorMedix CRMD Stock Holding History

EntryPoint Capital’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-36,665	Closed	-$452K	–	708
2025 Q2	$452K	Buy	36,665 +25,952	+242%	+$286K	0.23%	131
2025 Q1	$66K	Buy	+10,713	New	+$111K	0.03%	637

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EntryPoint Capital's CRMD Position: Q3 2025 in Review

EntryPoint Capital sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 36,665 shares — an estimated $452K sold.

EntryPoint Capital first reported a position in CRMD in Q1 2025 and held it in 2 quarters. The position peaked at $452K in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

EntryPoint Capital reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 36,665 CorMedix shares in Q3 2025, an estimated $452K.
EntryPoint Capital first reported a position in CorMedix in Q1 2025 and held it in 2 quarters.
EntryPoint Capital's CorMedix position peaked at $452K in Q2 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.